LECTURES SERIES ESBLs
-
Upload
nuhu-tanko -
Category
Documents
-
view
94 -
download
0
Transcript of LECTURES SERIES ESBLs
OVERVIEW OF EXTENDED
SPECTRUM BETA-LACTAMASES
(ESBLs)
DEPARTMENT OF PHARMACEUTICS AND
PHARMACEUTICAL MICROBIOLOGY
USMANU DANFODIYO UNIVERSITY, SOKOTO
NUHU, Tanko
30th June, 2016
Presentation Outline
Introduction
Beta-lactam antibiotics
Antimicrobial resistance
Beta-lactamases
Other definition of ESBLs
Methods of detection of ESBL production
July 16 2Overview of ESBLs Nuhu Tanko
Introduction
• The bactericidal effect of beta-lactam antibiotics
involves inhibition of cell wall synthesis.
• This effect occurs through covalent attachment to
PBP, which is a peptidoglycan transpeptidase
enzyme that catalyzes the final steps in cell wall
formation.
• The spectrum and effects of the different beta-
lactams are determined by the PBPs to which
these antibiotics bind.
July 16 3Overview of ESBLs Nuhu Tanko
Brief background of Beta-lactam (BL)
antibiotics• The 1st semi-synthetic cephalosporins were
introduced in the mid 1960s, and they showed asomewhat limited Gram-ve effect.
• In 2GC, coverage was expanded to include Gram-vebacteria in addition to the Gram+ve effect.
• The 3-GC (oxyimino-beta-lactams) offered extendedcoverage of Gram-ve bacteria and even better BLstability.
• In part, these cephalosporins were developedbecause of the discovery of narrow-spectrum beta-lactamases (e.g., TEM-1), and some of them alsohad good oral bioavailability.
July 16 4Overview of ESBLs Nuhu Tanko
• The Gram-ve effect was extended even further in
the 4-GC.
• A better Gram+ve effect was gained in the 5GC,
and this even applied to MRSA, and hence the
5GC are also called MRSA-active
cephalosporins.
• The cephamycins were developed in the 1970s.
• They proved to have the same antimicrobial
effect as the 2GC cephalosporins but were stable
against class A ESBLs.
July 16 5Overview of ESBLs Nuhu Tanko
• The carbapenems, were found to be highly
resistant to enzymatic hydrolysis.
• The 1st carbapenem (imipenem), which had to be
combined with cilastatin to protect it against renal
dehydropeptidase.
• The 2G of carbapenem, are resistant to renal
dehydropeptidase.
• The carbapenems are known to be the ONLY
antibiotics that have some degree of post-
antibiotic effect on infections with Gram-ve.
July 16 6Overview of ESBLs Nuhu Tanko
• The first monocyclic bacterially produced beta-
lactam antibiotics were named monobactams
(e.g., aztreonam).
• Monobactams have a good Gram-ve effect but
no useful Gram+ve effect, and they are stable
towards several beta-lactamases.
July 16 7Overview of ESBLs Nuhu Tanko
The menace called Antimicrobial
Resistance (AMR)
• Bacteria/microbes are remarkably resilient and
have developed ways to resist antibiotics/other
AM drugs.
• AMR is a resistance of microorganism to an AM
that was originally effective for treatment of
infections caused by it.
July 16 8Overview of ESBLs Nuhu Tanko
What are the Mechanism of
Resistance?
Destruction or inactivation of the antibiotic
Alteration or protection of the target site.
Reduction in cell surface permeability.
Metabolic by-pass.
July 16 9Overview of ESBLs Nuhu Tanko
• AMR can be:
Intrinsic resistance, or
Acquired resistance
• Factors promoting AMR:
Exposure to sub-optimal level of AM.
Exposure to broad spectrum AM.
Exposure to microbes carrying resistant genes.
Lack of hygiene in clinical environment.
Use of antibiotics in food and agriculture.
July 16 10Overview of ESBLs Nuhu Tanko
The Enzymes called Beta-lactamases (BLs)
• The BLs are the collective name of enzymes that
open the BL ring.
• Identified as a penicillinase or cephalosporinase on
the basis of the substrate hydrolysed.
• A water molecule is added to the common BL bond,
and this inactivates the BL antibiotic from penicillin
to carbapenems.
• Clinical effect of such hydrolyzation was not noted
until the beginning of the 1950s, when the first BL-
resistant S. aureus isolates appeared in hospitals.
July 16 11Overview of ESBLs Nuhu Tanko
What are these ESBLs?
• In 1983, Knothe found a single nucleotide mutation
in an SHV that represented the first plasmid-encoded
BL that could hydrolyze the extended-spectrum
cephalosporins in an isolate of K. ozaenae, and this
type was named SHV-2.
July 16 12Overview of ESBLs Nuhu Tanko
• ESBLs are defined as BLs that have the following
characteristics: they are transferable; they can
hydrolyze penicillins, 1st, 2nd, and 3rd GC, and
aztreonam (but not the cephamycins and
carbapenems); they can be blocked in vitro by
BLs inhibitors such as clavulanic acid.
• ESBL production is originally observed in E. coli and
Klebsiella spp., and has now been documented in
other Gram-ve bacilli, including Enterobacter spp.,
Proteus mirabilis and Providencia stuarti.
July 16 13Overview of ESBLs Nuhu Tanko
• Most ESBLs can be divided into three groups, which
are designated the TEM (approx. 200 variants), SHV
(over 140 variants), and CTX-M (approx. 130).
• In the beginning of the ESBL era, the clinical isolates
consisted of the TEMs and SHVs (mainly SHV-2 and
SHV-5).
July 16 14Overview of ESBLs Nuhu Tanko
• Members of the CTX-M group are now the most
common ESBLs worldwide.
• In Germany in 1989, an E. coli isolate that was
resistant to cefotaxime and produced a non-
TEM–non-SHV enzyme, was named CTX-M-1
due to its elevated activity against cefotaxime.
July 16 15Overview of ESBLs Nuhu Tanko
• The CTX-M enzymes can be classified into five
major groups, which are designated CTX-M-1, CTX-
M-2, CTX-M-8, CTX-M-9, and CTX-M-25.
• Each of these includes several plasmid-mediated
enzymes.
• For example, the CTX-M-1 group comprises CTX-
M-15 and several other types.
July 16 16Overview of ESBLs Nuhu Tanko
How can we detect ESBL production
in the laboratory?
• Can be Phenotypic or Genotypic.
• Increasing resistance to 3GC is predominantly
due to the production of ESBLs.
• Accurate laboratory detection is important to
avoid clinical failure due to inappropriate
antimicrobial therapy.
July 16 17Overview of ESBLs Nuhu Tanko
• As a general rule, laboratories should test all isolates
using both ceftazidime (the best indicator for
TEM and SHV-derived ESBLs) and cefotaxime
(the best indicator for CTX-M types).
• Alternative, they can test with cefpodoxime, as a
good indicator for all ESBL types.
• Earlier advice to screen only with ceftazidime is no
longer adequate in view of the emergence of CTX-M
types.
July 16 18Overview of ESBLs Nuhu Tanko
• Any organism showing reduced susceptibility to
cefotaxime, ceftazidime or cefpodoxime should
be investigated for ESBL production.
• Many different techniques exist for confirming
ESBL production but those utilising similar
methodology to standard susceptibility tests are
the most convenient for the routine diagnostic
laboratory.
• These all depend on detecting synergy between
clavulanic acid and the indicator
cephalosporin(s) used in the primary screening.
July 16 19Overview of ESBLs Nuhu Tanko
Each isolate should be considered a potential
ESBL-producer if the test results are as follows:
• Disk diffusion
Cefpodoxime < 22 mm
Ceftazidime < 22 mm
Cefotaxime < 27 mm
Ceftriaxone < 25 mm
Aztreonam < 27 mm
• MICs
Cefpodoxime > 2 µg/ml
Ceftazidime > 2 µg/ml
Cefotaxime > 2 µg/ml
Ceftriaxone > 2 µg/ml
Aztreonam > 2 µg/ml
July 16 Overview of ESBLs Nuhu Tanko 20
Double disc method
• Here it examines for the expansion of the
cephalosporin’s inhibition zone adjacent to a disc
containing Co-amoxiclav 20 + 10 mg.
• The agar is inoculated with the test organism to
give a semi-confluent growth.
• A ceftazidime 30 mg disc and an Co-amoxiclav
20+10 mg disc are then placed 25 - 30 mm apart,
centre-to-centre.
• This follow an overnight incubation in air at
37°C.
July 16 21Overview of ESBLs Nuhu Tanko
ESBL production is inferred when the zone of inhibition around the ceftazidime disc
is expanded by the clavulanate.
Additional extended-spectrum cephalosporins may be tested concurrently eg
cefotaxime (30 mg), aztreonam (30 mg) and ceftriaxone (30 mg), providing the Co-
amoxiclav disc is placed in the centre of the plate and the distance of 25 - 30 mm
between the cephalosporin and clavulanate-containing discs is observed.
The use of multiple cephalosporins may be helpful as ESBLs other than common
TEM and SHV mutants begin to spread.
July 16 22Overview of ESBLs Nuhu Tanko
Combination disc methods
• The zone of inhibition around a ‘combination’
disc containing the cephalosporin combined with
clavulanic acid is compared to the zone around a
disc containing the cephalosporin alone.
• An expansion of >5 mm or 50% (according to the
particular product and manufacturer’s guideline)
indicate ESBL production.
• Plates of test organisms are inoculated.July 16 23Overview of ESBLs Nuhu Tanko
• Pairs of discs containing an extended-spectrumcephalosporin (cefotaxime, ceftazidime orcefpodoxime) with and without clavulanic acidare placed on opposite sides of the sameinoculated plate.
• Zones of inhibition are measured followingovernight incubation in air at 37°C.
• The test organism is regarded as an ESBLproducer if the zone of inhibition around thecombination disc is at least 5 mm larger than thatof the cephalosporin alone, or if the zonediameter is expanded by 50% in the presence ofthe clavulanic acid.
July 16 24Overview of ESBLs Nuhu Tanko
CZC
CZ
CTC
CT
Based on CLSI recommendation, an increase in zone size > 5 mm than the zone when
tested alone will be accepted as confirmation of ESBL production.
July 16 25Overview of ESBLs Nuhu Tanko
ESBL Etest
• The detection of ESBLs by Etest is based on a
similar principle to that of the combination disc
method.
• Double-ended strips containing gradients of
cefotaxime or ceftazidime at one end and
cefotaxime or ceftazidime plus clavulanic acid at
the other end are tested in parallel.
• A decrease in MIC of 3 doubling dilutions in the
presence of clavulanate indicates ESBL
production.
July 16 26Overview of ESBLs Nuhu Tanko
July 16 27Overview of ESBLs Nuhu Tanko
Note
• Clinical isolates found to produce ESBLs should
be assumed to be resistant to all extended
spectrum cephalosporins irrespective of the
results of susceptibility testing.
• Not all resistance to 3GC due to ESBL
production - other potent BLs such as AmpC and
K1 enzymes may be responsible.
July 16 28Overview of ESBLs Nuhu Tanko
In Conclusion
• The presence of an ESBL-producing organism in aclinical infection can result in treatment failure if oneof the above classes of drugs is used.
• ESBLs can be difficult to detect because they havedifferent levels of activity against variouscephalosporins.
• Thus, the choice of which antimicrobial agents totest is critical. For example, one enzyme mayactively hydrolyze ceftazidime, resulting inceftazidime minimum inhibitory concentrations(MICs) of 256 µg/ml, but have poor activity oncefotaxime, producing MICs of only 4 µg/ml.
July 16 29Overview of ESBLs Nuhu Tanko
THANK YOU FOR LISTENING
July 16 30Overview of ESBLs Nuhu Tanko